ZyVersa Therapeutics (NASDAQ:ZVSA) & NuCana (NASDAQ:NCNA) Head-To-Head Review

NuCana (NASDAQ:NCNA) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Risk and Volatility

NuCana has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

Earnings and Valuation

This table compares NuCana and ZyVersa Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$34.37 million	($10.48)	-0.07
ZyVersa Therapeutics	N/A	N/A	-$98.30 million	N/A	N/A

Profitability

This table compares NuCana and ZyVersa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-314.47%	-112.60%
ZyVersa Therapeutics	N/A	-224.85%	-103.22%

Insider and Institutional Ownership

44.0% of NuCana shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 0.3% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for NuCana and ZyVersa Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	0	1	1	0	2.50
ZyVersa Therapeutics	0	0	1	0	3.00

NuCana presently has a consensus target price of $25.00, suggesting a potential upside of 3,187.31%. ZyVersa Therapeutics has a consensus target price of $120.00, suggesting a potential upside of 15,091.80%. Given ZyVersa Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe ZyVersa Therapeutics is more favorable than NuCana.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.